A phase II study to evaluate the efficacy of regorafenib in C-KIT mutated metastatic malignant melanoma patients who have progressed on first-line treatment: A Multicenter Trial of Korean Cancer Study Group (UN-14–13). (October 2022) - Kim, K.H.; Lee, H.J.; Lee, S.J.; Kim, M.; Ahn, M.S.; Choi, M.Y.; Lee, N.R.; Jung, M.; Shin, S.J.